Cipla announces formation of JV in China
The JV company will be in the business of manufacturing, selling and distribution of pharmaceutical products, research and development services, analytical development services with the purpose of providing high quality and affordable drugs.
As per the agreement, Cipla EU will hold 80% stake and Acebright will hold 20% stake in the JV Co. Cipla EU's investment in the JV Co. is estimated up to USD 24 million over a period of 4 years.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content